1. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet.
2003;362(9401):2089-2094.
2. American Gastroenterological Association policy statement on the use of
medical practice guidelines by managed care organizations and insurance
carriers. Gastroenterology. 1995;108(925): 6.
3. Marzolini C, Kim RB. Polymorhisms in human MDR1 (p-glycoprotein);Recent advances and clinical relevance Clin Pharmacol Ther. 2004;75(1):13-33.
4. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequencyof the C3435T mutation in exon 26 is significantly influenced by ethnicity.Pharmacogenetics. 2001;11(3): 217-21.
5. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in humanplacenta: Relation to genetic polymorphism of the multidrug resistance(MDR)-1 gene. J Pharmacol Exp Ther. 2001; 297(3):1137-1143.
6. Wandel C, Kim R.B, Kajiji S, et al. P-glycoprotein and cytochrome P–450
3A inhibition; KHU0Y dissociation of inhibitory potencies. Cancer Res.
1999;59(16):3944–3948.
7. Kobayashi M, Suzuki F, Akuta N, et al. Response to long-term lamivudine
treatment in patients infected with hepatitis B virus genotypes A, B, and
C. J Med Virol. 2006;78(10):1276-1283.
8. Yuen MF, Yuan HJ, Sablon E, et al. Long-term follow-up study of
Chinese patients with YMDD mutations: significance of hepatitis B virus
genotypes and characteristics of biochemical flares. J Clin Microbiol.
2004;42(9):3932-3936.
9. Yurdaydın C, Bozkaya H, Çetinkaya H, et al. Lamivudine vs lamivudine
and interferon combination treatment of HBeAg (-) chronic hepatitis B. J
Viral Hepat. 2005;12(3):262-268.
10. Sönmez E. Antiviral direnç monitorizasyonu ve klinik yararı. Klimik Derg.
2001;14(2):66-70.
11. Jardi R, Buti M, Rodriguez-Frias F, et al. Rapid detection of lamivudine
resistant hepatitis B virus polymerase gene variants. J Virol Methods.
1999;83(1-2):181-187.
12. Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention
of drug resistance. Clin Liver Dis. 2007;11(4):869-892.
13. Pallier C, Castéra L, Soulier A et al. Dynamics of hepatitis B virus
resistance to lamivudine. J Virol. 2006;80(2):643-653.
14. Chang UI, Lee YC, Wie SH, et al. Evolution of viral load and changes of
polimerase and precore/core promoter sequences in lamivudine-resistant
hepatitis B virus during adefovir therapy. J Med Virol. 2007;79(7):902-910.
15. Liu K, Hou W, Zumbika E, et al. Clinical features of chronic hepatitis B
patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ
SCIENCE B. 2005;6:1182-1187.
16. Si Ahmed N, Tavan D, Pichoud C, et al. Early detection of viral resistance
by determination of hepatitis B virus polymerase mutations in patients
treated by lamivudine for chronic hepatitis B. Hepatology. 2000;32(5):1078-
1088.
17. Suzuki F, Suzuki Y, Tsubota A, et al. Mutations of polymerase, precore and
core promoter gene in hepatitis B virus during 5-year lamivudine therapy.
J Hepatol. 2002;37(6):824-830.
18. Tang K, Ngoi SM, Gwee PC, et al. Disitnct haplotype profiles and strong
linkage disequilibirium at the MDR1 multidrug transporter gene locus in
three ethnic Asian populations. Pharmacogenetics. 2002;12(6):437-450.
19. Sakaeda T. MDR1 genotype-related pharmacogenetics: fact or fiction?
Drug Metab Pharmacokinet. 2005;20(6):391-414.
20. Schwab, Eichelbaum M, Fromm MF. Genetic polymorhisms of the human
MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43(1):285-
307.
21. Tsuruo T. Lida H. Tsukagoshi S, et al. Overcoming of vincristine resistance
in P388 leukemia in vivo and vitro through enhanced cytotoxicity of
vincristine and vinblastine by verapamil. Cancer Res. 1981;41(5):1967-
1972.
22. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia.
2000;14(3):467-473.
23. Takeshita H, Gebhardt MC, Springfield DS, et al. Experimental modelsfor the study of drug resistance in osteosarcoma: P-glycoprotein-positive,murine osteosarcoma cell lines. J Bone Joint Surg Am. 1996;78(3):366-375.
24. Tischler D, Weinberg K, Hinton DR, et al. MDR1 gene expression in brain
of patients with medically intractable epilepsy. Epilepsia. 1995;36(1):1-6.
25. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein
in the interaction of digoxin and rifampin. J Clin Invest. 1999;104(2):147-
153.
26. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T
MDRl gene polymorphism and susceptibility for ulcerative colitis.
Gastroenterology. 2003;124(1):26-33.
27. Lee W, Lochart C, Richard B, et al. Cancer pharmacogenomics: powerful
tools in cancer chemotherapy and drug development. The Oncologist.
2005;10(2):104-111.
28. Kimchi-Sarfaty C, Marple AH, Shinar S, et al. Ethnicity-relatedpolymorphisms and haplotypes in the human ABCB1 gene.Pharmacogenomics. 2007;8(1):29-39.
29. Fellay J, Mariolini C, Meaden ER, et al. Swiss HIV Cohort Study. Responseto antiretroviral treatment in HIV- 1 -infected individuals with allelicvariants of the multidrug resistance transporter 1: A pharmacogeneticsstudy. Lancet. 2002; 359(9300):30-36.
30. Timucin M, Alagozlu H, Ozdemir S, Ozdemir O. Association betweenABCB1 (MDR1) gene polymorphism and unresponsiveness combinedtherapy in chronic hepatitis C virus. Hepat Mon. 2013;13(4):e7522.